Thriva has secured a £4 million extension to its Series A funding round from venture capital firm Target Global.

This takes the London-based HealthTech startup's total funding to £11 million, following on from its initial £6 million fundraise last year, which included Guinness Asset Management and Pembroke VCT.

The investment will support expansion of its at-home health service. Its testing kits are processed by accredited labs which can analyse for indicators of heart disease and diabetes, vitamins, minerals and hormone function.

Thriva have processed over 115,000 test at-home blood tests since 2016, and claims that 76 of them have achieved an improvement in at least one of their biomarkers.

It is now launching personalised health plans and supplements as part of partnerships with hospitals and other healthcare providers looking to provide at-home testing.

The firm was founded by Hamish Grierson, Eliot Brooks and Tom Livesey, and has now expanded its team to 50 people.

Ricardo Schäfer, partner at Target Global, commented: “We are witnessing a shift in consumer behaviour towards an increasingly proactive approach to health: people want to know what’s going on inside their bodies.

“COVID-19 is further accelerating this trend, which requires remote blood testing," he continued, adding: "Thriva is playing an essential role in providing a solution for increasing the test volume."

At the start of the year, Thriva was named as one of the 30 companies joining Tech Nation's Upscale programme for the UK’s fastest growing scale-up tech companies.

Share Story: